DOCSLIB.ORG

Supplementary Table S1. Murine Prostatic Carcinogenesis Gene Codeset

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table S1. Murine Prostatic Carcinogenesis Gene Codeset Supplementary Table S1. Murine prostatic carcinogenesis gene codeset. Accession Gene NM_008935.1 prominin 1 (Prom1) NM_017471.2 probasin (Pbsn) NM_010113.3 epidermal growth factor (Egf) NM_010921.3 NK-3 transcription factor, locus 1 (Drosophila) Nkx3-1 NM_009735.3 beta-2 microglobulin (B2m) NM_013467.3 aldehyde dehydrogenase family 1, subfamily A1 (Aldh1a1) NM_011488.2 signal transducer and activator of transcription 5A (Stat5a) NM_008267.3 homeobox B13 (Hoxb13) NM_013891.4 SAM pointed domain containing ets transcription factor (Spdef) NM_010570.4 insulin receptor substrate 1 (Irs1) NM_008969.3 prostaglandin-endoperoxide synthase 1 (Ptgs1) NM_011254.5 retinol binding protein 1, cellular (Rbp1) NM_008160.5 glutathione peroxidase-1 (Gpx1) NM_011169.5 prolactin receptor (Prlr) NM_024264.3 cytochrome P450, family 27, subfamily a, polypeptide 1 (Cyp27a1) NM_007988.3 fatty acid synthase (Fasn) NM_133360.2 acetyl-coenzyme A carboxylase alpha (Acaca) NM_008255.1 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr) NM_001025250.3 vascular endothelial growth factor A (Vegfa) NM_011952.2 mitogen-activated protein kinase 3 (Mapk3) NM_007956.4 estrogen receptor 1 (alpha) (Esr1) NM_009805.4 CASP8 and FADD-like apoptosis regulator (Cflar) NM_007393.1 actin, beta, cytoplasmic (Actb) NM_007912.4 epidermal growth factor receptor (Egfr) NM_008402.2 integrin alpha V (Itgav) NM_008810.2 pyruvate dehydrogenase E1 alpha 1 (Pdha1) NM_008084.1 Gadph NM_009391.3 RAN, member RAS oncogene family (Ran) NM_010411.2 histone deacetylase 3 (Hdac3) NM_011697.2 vascular endothelial growth factor B (Vegfb) NM_010664.1 keratin 18 (Krt18) NM_009875.4 cyclin-dependent kinase inhibitor 1B (Cdkn1b) NM_031869.2 protein kinase, AMP-activated, beta 1 non-catalytic subunit (Prkab1) NM_001003817.1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2) NM_008714.2 Notch gene homolog 1 (Drosophila) (Notch1) NM_008540.2 SMAD family member 4 (Smad4) NM_019827.3 glycogen synthase kinase 3 beta (Gsk3b) NM_177821.6 E1A binding protein p300 (Ep300) NM_008562.3 myeloid cell leukemia sequence 1 (Mcl1) NM_009864.2 cadherin 1 (Cdh1) NM_013476.3 androgen receptor (Ar) NM_008678.2 nuclear receptor coactivator 2 (Ncoa2) NM_009743.4 BCL2-like 1 (Bcl2l1) NM_008679.3 nuclear receptor coactivator 3 (Ncoa3) NM_008689.2 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 (Nfkb1) NM_019812.1 sirtuin 1 (silent mating type information regulation 2, homolog) 1 (S. cerevisiae) (Sirt1) NM_007614.3 catenin (cadherin associated protein), beta 1 (Ctnnb1) NM_133915.2 paxillin (Pxn) NM_016769.3 MAD homolog 3 (Drosophila) (Smad3) NM_011305.3 retinoid X receptor alpha (Rxra) NM_010559.2 interleukin 6 receptor, alpha (Il6ra) NM_008591.1 met proto-oncogene (Met) NM_009367.1 transforming growth factor, beta 2 (Tgfb2) NM_011486.4 signal transducer and activator of transcription 3 (Stat3), transcript variant 3 NM_007544.3 BH3 interacting domain death agonist (Bid) NM_011113.3 plasminogen activator, urokinase receptor (Plaur) NM_028835.1 autophagy-related 7 (yeast) (Atg7) NM_001177352.1 myelocytomatosis oncogene (Myc) NM_019739.2 forkhead box O1 (Foxo1) NM_001122733.1 kit oncogene (Kit) NM_015733.4 caspase 9 (Casp9) NM_007913.5 early growth response 1 (Egr1) NM_007836.1 growth arrest and DNA-damage-inducible 45 alpha (Gadd45a) NM_010568.2 insulin receptor (Insr) NM_007527.3 BCL2-associated X protein (Bax) NM_021284.5 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) NM_011400.3 solute carrier family 2 (facilitated glucose transporter), member 1 (Slc2a1) NM_010358.5 glutathione S-transferase, mu 1 (Gstm1) NM_008960.2 phosphatase and tensin homolog (Pten) NM_010513.2 insulin-like growth factor I receptor (Igf1r) NM_011480.1 sterol regulatory element binding factor 1 (Srebf1) NM_053069.5 autophagy related 5 (Atg5) NM_010431.2 hypoxia inducible factor 1, alpha subunit (Hif1a) NM_009652.2 thymoma viral proto-oncogene 1 (Akt1) NM_008228.2 histone deacetylase 1 (Hdac1) NM_008229.2 histone deacetylase 2 (Hdac2) NM_013671.3 superoxide dismutase 2, mitochondrial (Sod2) NM_008259.3 forkhead box A1 (Foxa1) NM_009812.2 caspase 8 (Casp8) NM_011308.2 nuclear receptor co-repressor 1 (Ncor1) NM_009029.2 retinoblastoma 1 (Rb1) NM_007610.1 caspase 2 (Casp2) NM_011640.1 transformation related protein 53 (Trp53) NM_001111075.2 cell division cycle 25 homolog B (S. pombe) (Cdc25b) NM_009870.3 cyclin-dependent kinase 4 (Cdk4) NM_007415.2 poly (ADP-ribose) polymerase family, member 1 (Parp1) NM_011045.2 proliferating cell nuclear antigen (Pcna) NM_010066.3 DNA methyltransferase (cytosine-5) 1 (Dnmt1) NM_007971.2 enhancer of zeste homolog 2 (Drosophila) (Ezh2) NM_016756.4 cyclin-dependent kinase 2 (Cdk2) NM_009810.2 caspase 3 (Casp3) NM_007499.1 ataxia telangiectasia mutated homolog (human) (Atm) NM_009765.2 breast cancer 2 (Brca2) NM_010881.2 nuclear receptor coactivator 1 (Ncoa1) NM_001110208.1 thymoma viral proto-oncogene 2 (Akt2) NM_207225.1 histone deacetylase 4 (Hdac4) NM_020009.2 mechanistic target of rapamycin (serine/threonine kinase) (Mtor) NM_010413.3 histone deacetylase 6 (Hdac6) NM_007669.4 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a) NM_008360.1 interleukin 18 (Il18) NM_133217.3 beta-carotene oxygenase 2 (Bco2) NM_007522.2 BCL2-associated agonist of cell death (Bad) NM_010157.3 estrogen receptor 2 (beta) (Esr2) NM_201645.1 UDP glucuronosyltransferase 1 family, polypeptide A1 (Ugt1a1) NM_173371.3 hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) (H6pd) NM_139294.5 Braf transforming gene (Braf) NM_011146.1 peroxisome proliferator activated receptor gamma (Pparg) NM_009504.3 vitamin D receptor (Vdr) NM_008302.3 heat shock protein 90 alpha (cytosolic), class B member 1 (Hsp90ab1) NM_175283.3 steroid 5 alpha-reductase 1 (Srd5a1) NM_011434.1 superoxide dismutase 1, soluble (Sod1) NM_001033988.1 nuclear receptor coactivator 4 (Ncoa4) NM_019584.3 beclin 1, autophagy related (Becn1) NM_011949.3 mitogen-activated protein kinase 1 (Mapk1) NM_001081117.2 antigen identified by monoclonal antibody Ki 67 (Mki67) NM_007630.2 cyclin B2 (Ccnb2) NM_009689.2 baculoviral IAP repeat-containing 5 (Birc5) NM_011496.1 aurora kinase B (Aurkb) NM_008021.4 forkhead box M1 (Foxm1) NM_011497.3 aurora kinase A (Aurka) NM_001037134.1 cyclin E2 (Ccne2) NM_009764.3 breast cancer 1 (Brca1) NM_007891.4 E2F transcription factor 1 (E2f1) NM_009860.2 cell division cycle 25C (Cdc25c) NM_007659.3 cyclin-dependent kinase 1 (Cdk1) NM_177382.3 cytochrome P450, family 2, subfamily r, polypeptide 1 (Cyp2r1) NM_001040654.1 cyclin-dependent kinase inhibitor 2A (Cdkn2a) NM_009354.1 telomerase reverse transcriptase (Tert) NM_008342.2 insulin-like growth factor binding protein 2 (Igfbp2) NM_172301.3 cyclin B1 (Ccnb1) NM_001163028.1 beta-carotene 15,15'-monooxygenase (Bcmo1) NM_007489.3 aryl hydrocarbon receptor nuclear translocator-like (Arntl) NM_008970.3 parathyroid hormone-like peptide (Pthlh) NM_008161.2 glutathione peroxidase 3 (Gpx3) NM_013541.1 glutathione S-transferase, pi 1 (Gstp1) NM_001012335.1 midkine (Mdk) NM_010738.2 lymphocyte antigen 6 complex, locus A (Ly6a) NM_011577.1 transforming growth factor, beta 1 (Tgfb1) NM_009371.2 transforming growth factor, beta receptor II (Tgfbr2) NM_007616.3 caveolin 1, caveolae protein (Cav1) NM_011701.4 vimentin (Vim) NM_008816.2 platelet/endothelial cell adhesion molecule 1 (Pecam1) NM_001111059.1 CD34 antigen (Cd34) NM_010288.3 gap junction protein, alpha 1 (Gja1) NM_008610.2 matrix metallopeptidase 2 (Mmp2) NM_008006.2 fibroblast growth factor 2 (Fgf2) NM_001083316.1 platelet derived growth factor receptor, alpha polypeptide (Pdgfra) NM_009851.2 CD44 antigen (Cd44) NM_008343.2 insulin-like growth factor binding protein 3 (Igfbp3) NM_001113530.1 colony stimulating factor 1 (macrophage) (Csf1) NM_001079908.1 fibroblast growth factor receptor 1 (Fgfr1) NM_010591.2 Jun oncogene (Jun) NM_009829.3 cyclin D2 (Ccnd2) NM_010427.4 hepatocyte growth factor (Hgf) NM_009662.2 arachidonate 5-lipoxygenase (Alox5) NM_009741.3 B cell leukemia/lymphoma 2 (Bcl2) NM_007960.3 ets variant gene 1 (Etv1) NM_013599.2 matrix metallopeptidase 9 (Mmp9) NM_011333.3 chemokine (C-C motif) ligand 2 (Ccl2) NM_009365.2 transforming growth factor beta 1 induced transcript 1 (Tgfb1i1) NM_207668.2 acid phosphatase, prostate (Acpp) NM_008809.1 platelet derived growth factor receptor, beta polypeptide (Pdgfrb) NM_013693.1 tumor necrosis factor (Tnf) NM_009263.3 secreted phosphoprotein 1 (Spp1) NM_011347.1 selectin, platelet (Selp) NM_009807.2 caspase 1 (Casp1) NM_033217.3 nerve growth factor receptor (TNFR superfamily, member 16) (Ngfr) NM_009305.2 synaptophysin (Syp) NM_007664.4 cadherin 2 (Cdh2) NM_010518.2 insulin-like growth factor binding protein 5 (Igfbp5) NM_015775.2 transmembrane protease, serine 2 (Tmprss2) NM_007631.1 cyclin D1 (Ccnd1) NM_011641.2 transformation related protein 63 (Trp63) NM_009170.3 sonic hedgehog (Shh) NM_027011.2 keratin 5 (Krt5) NM_009873.2 cyclin-dependent kinase 6 (Cdk6) NM_007556.2 bone morphogenetic protein 6 (Bmp6) NM_011243.1 retinoic acid receptor, beta (Rarb) NM_008815.2 ets variant gene 4 (E1A enhancer binding protein, E1AF) (Etv4) NM_011198.3 prostaglandin-endoperoxide synthase 2 (Ptgs2) NM_133659.2 avian erythroblastosis virus E-26 (v-ets) oncogene related (Erg) NM_013614.2 ornithine decarboxylase, structural 1 (Odc1) NM_001146100.1 hexokinase 1 (Hk1) NM_010554.4 interleukin 1 alpha (Il1a) NM_053188.2 steroid 5 alpha-reductase 2 (Srd5a2) NM_001111274.1 insulin-like growth factor 1 (Igf1) NM_007825.2 cytochrome P450, family 7, subfamily b, polypeptide 1 (Cyp7b1) NM_010228.3 FMS-like tyrosine kinase 1 (Flt1) .
Load more

Recommended publications
  • The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival In
    www.nature.com/scientificreports OPEN The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Received: 20 October 2017 Accepted: 2 February 2018 Promotes Tumor Cell Survival in Published: xx xx xxxx Neurospheres Andrew S. Gilder1, Letizia Natali1, Danielle M. Van Dyk1, Cristina Zalfa1, Michael A. Banki1, Donald P. Pizzo1, Huawei Wang 1, Richard L. Klemke1, Elisabetta Mantuano 1,2 & Steven L. Gonias1 PLAUR encodes the urokinase receptor (uPAR), which promotes cell survival, migration, and resistance to targeted cancer therapeutics in glioblastoma cells in culture and in mouse model systems. Herein, we show that patient survival correlates inversely with PLAUR mRNA expression in gliomas of all grades, in glioblastomas, and in the subset of glioblastomas that demonstrate the mesenchymal gene expression signature. PLAUR clusters with genes that defne the more aggressive mesenchymal subtype in transcriptome profles of glioblastoma tissue and glioblastoma cells in neurospheres, which are enriched for multipotent cells with stem cell-like qualities. When PLAUR was over-expressed or silenced in glioblastoma cells, neurosphere growth and expression of mesenchymal subtype biomarkers correlated with uPAR abundance. uPAR also promoted glioblastoma cell survival in neurospheres. Constitutively-active EGF Receptor (EGFRvIII) promoted neurosphere growth; however, unlike uPAR, EGFRvIII did not induce the mesenchymal gene expression signature. Immunohistochemical analysis of human glioblastomas showed that uPAR is typically expressed by a small sub-population of the cancer cells; it is thus reasonable to conclude that this subpopulation of cells is responsible for the efects of PLAUR on patient survival. We propose that uPAR-expressing glioblastoma cells demonstrate a mesenchymal gene signature, an increased capacity for cell survival, and stem cell-like properties.
    [Show full text]
  • Mechanical Forces Induce an Asthma Gene Signature in Healthy Airway Epithelial Cells Ayşe Kılıç1,10, Asher Ameli1,2,10, Jin-Ah Park3,10, Alvin T
    www.nature.com/scientificreports OPEN Mechanical forces induce an asthma gene signature in healthy airway epithelial cells Ayşe Kılıç1,10, Asher Ameli1,2,10, Jin-Ah Park3,10, Alvin T. Kho4, Kelan Tantisira1, Marc Santolini 1,5, Feixiong Cheng6,7,8, Jennifer A. Mitchel3, Maureen McGill3, Michael J. O’Sullivan3, Margherita De Marzio1,3, Amitabh Sharma1, Scott H. Randell9, Jefrey M. Drazen3, Jefrey J. Fredberg3 & Scott T. Weiss1,3* Bronchospasm compresses the bronchial epithelium, and this compressive stress has been implicated in asthma pathogenesis. However, the molecular mechanisms by which this compressive stress alters pathways relevant to disease are not well understood. Using air-liquid interface cultures of primary human bronchial epithelial cells derived from non-asthmatic donors and asthmatic donors, we applied a compressive stress and then used a network approach to map resulting changes in the molecular interactome. In cells from non-asthmatic donors, compression by itself was sufcient to induce infammatory, late repair, and fbrotic pathways. Remarkably, this molecular profle of non-asthmatic cells after compression recapitulated the profle of asthmatic cells before compression. Together, these results show that even in the absence of any infammatory stimulus, mechanical compression alone is sufcient to induce an asthma-like molecular signature. Bronchial epithelial cells (BECs) form a physical barrier that protects pulmonary airways from inhaled irritants and invading pathogens1,2. Moreover, environmental stimuli such as allergens, pollutants and viruses can induce constriction of the airways3 and thereby expose the bronchial epithelium to compressive mechanical stress. In BECs, this compressive stress induces structural, biophysical, as well as molecular changes4,5, that interact with nearby mesenchyme6 to cause epithelial layer unjamming1, shedding of soluble factors, production of matrix proteins, and activation matrix modifying enzymes, which then act to coordinate infammatory and remodeling processes4,7–10.
    [Show full text]
  • Cómo Citar El Artículo Número Completo Más Información Del
    Revista de Biología Tropical ISSN: 0034-7744 ISSN: 0034-7744 Universidad de Costa Rica Alpízar-Alpízar, Warner; Malespín-Bendaña, Wendy; Une, Clas; Ramírez-Mayorga, Vanessa Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer Revista de Biología Tropical, vol. 66, núm. 1, 2018, pp. 28-47 Universidad de Costa Rica DOI: 10.15517/rbt.v66i1.29014 Disponible en: http://www.redalyc.org/articulo.oa?id=44955366003 Cómo citar el artículo Número completo Sistema de Información Científica Redalyc Más información del artículo Red de Revistas Científicas de América Latina y el Caribe, España y Portugal Página de la revista en redalyc.org Proyecto académico sin fines de lucro, desarrollado bajo la iniciativa de acceso abierto Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer Warner Alpízar-Alpízar1,2*, Wendy Malespín-Bendaña3, Clas Une3 & Vanessa Ramírez-Mayorga3,4 1. Centro de Investigación en Estructuras Microscópicas (CIEMic), Universidad de Costa Rica, San José, Costa Rica; [email protected] 2. Departamento de Bioquímica, Escuela de Medicina, Universidad de Costa Rica, San José, Costa Rica. 3. Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San José, Costa Rica; [email protected], [email protected], [email protected] 4. Sección de Nutrición Pública, Escuela de Nutrición, Universidad de Costa Rica, San José, Costa Rica. * Correspondence Received 14-VII-2017. Corrected 18-X-2017. Accepted 16-XI-2017. Abstract: Gastric cancer is ranked as the third death-causing cancer and one of the most incident malignancies worldwide.
    [Show full text]
  • Tamoxifen Erythroid Toxicity Revealed by Studying the Role of Nuclear
    COMMENT as in Santana-Codina et al.1 Briefly, 12-week old Sv129/J Tamoxifen erythroid toxicity revealed by studying Ncoa4-ko and wild-type littermates received 200 mg/kg the role of nuclear receptor co-activator 4 in tamoxifen via oral gavage daily for five consecutive days erythropoiesis (day 0-4) and complete blood count was obtained at days 0, 4, 11 and 21. We chose mice on Sv129/J background We read with great interest the paper recently pub- that, unlike C57BL/6 Ncoa4-ko animals,4 do not show lished by Santana-Codina et al.1 about the cell anemia or alterations of iron parameters but only mild autonomous and non-autonomous role of nuclear recep- microcytosis (Figure 1 and Nai et al., 2019, manuscript in tor co-activator 4 (NCOA4). NCOA4 is a cargo receptor preparation). At day 4, only Ncoa4-ko mice showed a sta- that, in conditions of iron deficiency, promotes fer- tistically significant decrease in red blood cell (RBC) ritinophagy to release iron from ferritin.2,3 Inactivation of count, and hematocrit (Hct) and hemoglobin (Hb) levels. Ncoa4 in C57BL/6 mice causes mild microcytic anemia and increases the susceptibility to iron-deficiency anemia At day 11, also wild-type mice showed a reduction in due to iron being trapped in ferritin in several organs.3,4 To RBC count and decreased Hb and Hct, although for the formally prove the role of Ncoa4 inactivation on erythro- latter two parameters levels were higher than those of poiesis, a tamoxifen-inducible CRE-dependent Ncoa4-ko mice.
    [Show full text]
  • NCOA4 Maintains Murine Erythropoiesis Via Cell Autonomous and Non-Autonomous Mechanisms
    Red Cell Biology & its Disorders SUPPLEMENTARY APPENDIX NCOA4 maintains murine erythropoiesis via cell autonomous and non-autonomous mechanisms Naiara Santana-Codina,1,* Sebastian Gableske,1,* Maria Quiles del Rey,1 Beata Małachowska,2,3 Mark P. Jedrychowski,1,4 Douglas E. Biancur,1 Paul J. Schmidt,5 Mark D. Fleming,5 Wojciech Fendler,1,2 J. Wade Harper,4,# Alec C. Kimmelman6,# and Joseph D. Mancias1 1Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2De- partment of Biostatistics and Translational Medicine, Medical University of Lodz, Poland; 3Postgraduate School of Molecular Medicine, Medical University of Warsaw, Poland; 4Department of Cell Biology, Harvard Medical School, Boston, MA, USA; 5Department of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA and 6Department of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA * These authors contributed equally to this work ©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.204123 Received: August 10, 2018. Accepted: January 9, 2019. Pre-published: January 10, 2019. Correspondence: JOSEPH D. MANCIAS - [email protected] SUPPLEMENTARY INFORMATION SUPPLEMENTAL EXPERIMENTAL PROCEDURES Cell culture. Cells were cultured in a humidified incubator at 37°C and 5% carbon dioxide (CO2). HEK-293T and K562 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, Virginia) and tested for mycoplasma contamination by PCR. Cells were grown in DMEM (HEK-293T, Life Technologies, 11965) or IMDM (K562, Thermo Fisher 12440053) with 10% FBS and 1% Pen/Strep (Life Technologies 15140).
    [Show full text]
  • Receptor-Like 1 and -Like 2 Is an Endogenous Ligand for Formyl Peptide Through a Urokinase Receptor Epitope That Urokinase Induc
    Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 2 This information is current as of May 10, 2019. Amato de Paulis, Nunzia Montuori, Nella Prevete, Isabella Fiorentino, Francesca Wanda Rossi, Valeria Visconte, Guido Rossi, Gianni Marone and Pia Ragno J Immunol 2004; 173:5739-5748; ; doi: 10.4049/jimmunol.173.9.5739 http://www.jimmunol.org/content/173/9/5739 Downloaded from References This article cites 65 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/173/9/5739.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on May 10, 2019 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 21 Amato de Paulis,* Nunzia Montuori,† Nella Prevete,* Isabella Fiorentino,* Francesca Wanda Rossi,* Valeria Visconte,‡ Guido Rossi,‡ Gianni Marone,2* and Pia Ragno† Basophils circulate in the blood and are able to migrate into tissues at sites of inflammation.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 32-3099: PRKAB1 Recombinant Protein Description
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-3099: PRKAB1 Recombinant Protein Alternative Name : AMPK,HAMPKb,5'-AMP-activated protein kinase subunit beta-1,AMPK subunit beta-1,AMPKb,PRKAB1. Description Source : E.coli. PRKAB1 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 293 amino acids (1-270 a.a.) and having a molecular mass of 32.8 kDa. The PRKAB1 is fused to a 23 amino acid His Tag at N- Terminus and purified by proprietary chromatographic techniques. 5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) hinders protein, carbohydrate and lipid biosynthesis, in addition to cell growth and proliferation. AMPK is a heterotrimer comprised of an alpha catalytic subunit, and non-catalytic beta and gamma subunits. AMPK acts via direct phosphorylation of metabolic enzymes, and longer-term effects by phosphorylation of transcription regulators. PRKAB1 is a regulator of cellular polarity by remodeling the actin cytoskeleton; most likely by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex compiles, through its C-terminus that joins alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3). Product Info Amount : 5 µg Purification : Greater than 85% as determined by SDS-PAGE. The PRKAB1 protein solution (0.5mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, Content : 10% glycerol and 1mM DTT. Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of Storage condition : time.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • RET/PTC Activation in Papillary Thyroid Carcinoma
    European Journal of Endocrinology (2006) 155 645–653 ISSN 0804-4643 INVITED REVIEW RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture Massimo Santoro1, Rosa Marina Melillo1 and Alfredo Fusco1,2 1Istituto di Endocrinologia ed Oncologia Sperimentale del CNR ‘G. Salvatore’, c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, University ‘Federico II’, Via S. Pansini, 5, 80131 Naples, Italy and 2NOGEC (Naples Oncogenomic Center)–CEINGE, Biotecnologie Avanzate & SEMM, European School of Molecular Medicine, Naples, Italy (Correspondence should be addressed to M Santoro; Email: [email protected]) Abstract Papillary thyroid carcinoma (PTC) is frequently associated with RET gene rearrangements that generate the so-called RET/PTC oncogenes. In this review, we examine the data about the mechanisms of thyroid cell transformation, activation of downstream signal transduction pathways and modulation of gene expression induced by RET/PTC. These findings have advanced our understanding of the processes underlying PTC formation and provide the basis for novel therapeutic approaches to this disease. European Journal of Endocrinology 155 645–653 RET/PTC rearrangements in papillary growth factor, have been described in a fraction of PTC thyroid carcinoma patients (7). As illustrated in figure 1, many different genes have been found to be rearranged with RET in The rearranged during tansfection (RET) proto-onco- individual PTC patients. RET/PTC1 and 3 account for gene, located on chromosome 10q11.2, was isolated in more than 90% of all rearrangements and are hence, by 1985 and shown to be activated by a DNA rearrange- far, the most frequent variants (8–11). They result from ment (rearranged during transfection) (1).As the fusion of RET to the coiled-coil domain containing illustrated in Fig.
    [Show full text]
  • Orally Bioavailable Androgen Receptor Degrader, Potential Next
    Published OnlineFirst September 3, 2019; DOI: 10.1158/1078-0432.CCR-19-1458 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer Suriyan Ponnusamy1, Yali He2, Dong-Jin Hwang2, Thirumagal Thiyagarajan1, Rene Houtman3,Vera Bocharova4, Bobby G. Sumpter4, Elias Fernandez5, Daniel Johnson6, Ziyun Du7, Lawrence M. Pfeffer7, Robert H. Getzenberg8, Iain J. McEwan9, Duane D. Miller2, and Ramesh Narayanan1,10 Abstract Purpose: Androgen receptor (AR)-targeting prostate Results: UT-34 inhibits the wild-type and LBD-mutant cancer drugs, which are predominantly competitive ARs comparably and inhibits the in vitro proliferation and ligand-binding domain (LBD)-binding antagonists, are in vivo growth of enzalutamide-sensitive and -resistant pros- inactivated by common resistance mechanisms. It is tate cancer xenografts. In preclinical models, UT-34 induced important to develop next-generation mechanistically theregressionofenzalutamide-resistanttumorsatdoses distinct drugs to treat castration- and drug-resistant pros- when the AR is degraded; but, at lower doses, when the AR tate cancers. is just antagonized, it inhibits, without shrinking, the Experimental Design: Second-generation AR pan antag- tumors. This indicates that degradation might be a prereq- onist UT-34 was selected from a library of compounds uisite for tumor regression. Mechanistically, UT-34 promotes and tested in competitive AR binding and transactivation
    [Show full text]
  • Genetic Variant in 3' Untranslated Region of the Mouse Pycard Gene
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.26.437184; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 2 3 Title: 4 Genetic Variant in 3’ Untranslated Region of the Mouse Pycard Gene Regulates Inflammasome 5 Activity 6 Running Title: 7 3’UTR SNP in Pycard regulates inflammasome activity 8 Authors: 9 Brian Ritchey1*, Qimin Hai1*, Juying Han1, John Barnard2, Jonathan D. Smith1,3 10 1Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, 11 Cleveland, OH 44195 12 2Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 13 44195 14 3Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western 15 Reserve University, Cleveland, OH 44195 16 *, These authors contributed equally to this study. 17 Address correspondence to Jonathan D. Smith: email [email protected]; ORCID ID 0000-0002-0415-386X; 18 mailing address: Cleveland Clinic, Box NC-10, 9500 Euclid Avenue, Cleveland, OH 44195, USA. 19 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.26.437184; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 20 Abstract 21 Quantitative trait locus mapping for interleukin-1 release after inflammasome priming and activation 22 was performed on bone marrow-derived macrophages (BMDM) from an AKRxDBA/2 strain intercross.
    [Show full text]